Skip to main content

Table 3 Comparisons of CrAg positivity, incidence of CM and all-cause mortality among HIV-infected persons stratified by CD4+ T cell count

From: The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis

Author, year

Prevalence of CrAg positivity

Incidence of CM

All-cause mortality

CD4<100 (cells/μL)

CD4 100 ~ 200 (cells/μL)

CD4<100 (cells/μL)

CD4 100 ~ 200 (cells/μL)

CD4<100 (cells/μL)

CD4 100 ~ 200 (cells/μL)

with antifungal treatment

without antifungal treatment

with antifungal treatment

without antifungal treatment

with antifungal treatment

without antifungal treatment

with antifungal treatment

without antifungal treatment

 Chariyalertsak, 2002 [25]

Not reported

0 of 40

6 of 45

0 of 23

0 of 21

Not reported

Not reported

 Parkes-Ratanshi, 2011 [18]

Not reported

17 of 698

2 of 821

3a of 698

0a of 821

 McKinsey, 1999 [19]

Not reported

0 of 101

7 of 103

1 of 48

1 of 43

Not reported

Not reported

 Meya, 2010 [21]

26 of 295

7 of 298

3 of 21

2 of 5

Not reported

6 of 21

5 of 5

0 of 4

1 of 3

 Govender, 2015 [1]

20 of 708

6 of 371

Not reported

Not reported

Not reported

Not reported

 Borges, 2019 [24]

12 of 159

5 of 5

0 of 9

0 of 3

0 of 1

1 of 4

Not reported

Not reported

 

Pooled CrAg + prevalence:

0.06 [−0.02, 0.11], p = 0.001, I2 = 86.5%

Pooled CrAg + prevalence:

0.02 [0.01, 0.03], p = 0.146, I2 = 48%

Risk ratio with 95%CI:

7.67 [2.03, 29.05], p = 0.36, I2 = 1%

Risk ratio with 95%CI:

1.15 [0.16, 8.13],

p = 0.97, I2 = 0%

Risk ratio with 95%CI:

0.32 [0.16, 0.64], p and I2 not applicable

Risk ratio with 95%CI:

0.27 [0.01, 4.93], p and I2 not applicable

Risk ratio with 95%CI

1.82 [0.77, 4.30], p = 0.007, I2 = 63%

2.53 [0.50, 12.71], p = 0.26, I2 = 59%

4.15 [0.89, 19.42], p = 0.07, I2 = 0%

  1. a Died within 4 weeks